Business
ORYZON Announces the Voting Results of December 2025 Extraordinary General Shareholders' Meeting
37.8% of voting rights present or representedAll resolutions were approved MADRID and CAMBRIDGE, Mass., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and global leader in epigenetics, today announced the results of voting at the Extraordinary General Shareholders' Meeting held last Friday in Madrid. A total of 33,581,589 of the Company's issued and outstanding voting rights (representing 37.7938% of the share cap
About this update from Oryzon Genomics Sa
[{"type":"image","alt":"Oryzon Genomics, S.A.","displaySize":"","headline":null,"caption":"Oryzon Genomics, S.A.","className":"","disableSlideshowImg":false,"size":{"original":{"width":182,"height":70,"url":"https://media.zenfs.com/en/globenewswire.com/371936053f3f3aceeaf8ca929a3547e2"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/cNdaqSWVXmpOQnfrePXGFw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTM2MDtoPTEzODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/371936053f3f3aceeaf8ca929a3547e2","width":182,"height":70}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"37.8% of voting rights present or represented","length":45,"tagName":"p"}]},{"val":[{"type":"text","content":"All resolutions were approved","length":29,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":74,"olType":false},{"type":"text","content":"MADRID and CAMBRIDGE, Mass., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and global leader in epigenetics, today announced the results of voting at the Extraordinary General Shareholders' Meeting held last Friday in Madrid. A total of 33,581,589 of the Company's issued and outstanding voting rights (representing 37.7938% of the share capital) were at the Meeting, either in person or represented by proxy.","length":501,"tagName":"p"},{"type":"text","content":"The Company's shareholders approved all of the resolutions listed below, proposed by the Board of Directors at the Company's Extraordinary General Shareholders’ Meeting, with favorable votes ranging from 93% to 98%.","length":223,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Technical amendment of Article 2 of the Company’s Bylaws, relating to the corporate purpose, to adapt it to the New National Classification of Economic Activities (CNAE 2025).","length":175,"tagName":"p"}]},{"val":[{"type":"text","content":"Amendment of Article 11 of the Company’s Bylaws, relating to the remuneration of the Board of Directors.","length":104,"tagName":"p"}]},{"val":[{"type":"text","content":"Approval of the new Remuneration Policy for directors, to be applied from the date of its approval and for the following three financial years, that is, during the 2026, 2027, and 2028 financial years.","length":201,"tagName":"p"}]},{"val":[{"type":"text","content":"...